Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
186RNL in Pediatric Ependymoma and High-Grade Glioma
NCT07061626Phase 1Recruiting
- Sponsor
- Cerenome
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of rhenium (186Re) obisbemeda in ependymoma and glioma (4 arms), sponsored by Cerenome. Primary endpoints: Maximum Tolerated Dose at 28 days, Overall Response Rate by RANO in Ependymoma at 90 days and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
rhenium (186Re) obisbemeda
03
Conditions
ependymomaglioma
Beyond the preview
Go deeper on NCT07061626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061626.